Cargando…
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
SIMPLE SUMMARY: Many bilateral breast cancer patients with increased hereditary susceptibility to breast cancer result negative for BRCA1 or BRCA2 pathogenic variants and, thus, need a further genetic testing through a broader gene panel. Some patients with negative test result for BRCA1/2 pathogeni...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564956/ https://www.ncbi.nlm.nih.gov/pubmed/32854451 http://dx.doi.org/10.3390/cancers12092415 |
_version_ | 1783595830360408064 |
---|---|
author | Fanale, Daniele Incorvaia, Lorena Filorizzo, Clarissa Bono, Marco Fiorino, Alessia Calò, Valentina Brando, Chiara Corsini, Lidia Rita Barraco, Nadia Badalamenti, Giuseppe Russo, Antonio Bazan, Viviana |
author_facet | Fanale, Daniele Incorvaia, Lorena Filorizzo, Clarissa Bono, Marco Fiorino, Alessia Calò, Valentina Brando, Chiara Corsini, Lidia Rita Barraco, Nadia Badalamenti, Giuseppe Russo, Antonio Bazan, Viviana |
author_sort | Fanale, Daniele |
collection | PubMed |
description | SIMPLE SUMMARY: Many bilateral breast cancer patients with increased hereditary susceptibility to breast cancer result negative for BRCA1 or BRCA2 pathogenic variants and, thus, need a further genetic testing through a broader gene panel. Some patients with negative test result for BRCA1/2 pathogenic variants may harbor pathogenic variants in other breast cancer susceptibility genes, including ATM, CHEK2, PALB2, PTEN, TP53. Of course, the use of a multi-gene panel provides clinicians more information through a single test. Therefore, we focused on potential clinical impact of a NGS-based multi-gene panel testing in bilateral breast cancer patients, in order to evaluate the utility of perform a most comprehensive genetic analysis in these subjects, regardless the criteria concerning personal and family history of cancer established by the current guidelines. Our study revealed that the use of a NGS-based multiple-gene panel testing could increase the detection rates of germline alterations in bilateral breast cancer patients. ABSTRACT: Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast cancer (BBC). The annual risk of contralateral BC is about 0.5%, but increases by up to 3% in BRCA1 or BRCA2 pathogenic variant (PV) carriers. Our study was aimed to evaluate whether all BBC patients should be offered multi-gene panel testing, regardless their cancer family history and age at diagnosis. We retrospectively collected all clinical information of 139 BBC patients genetically tested for germline PVs in different cancer susceptibility genes by NGS-based multi-gene panel testing. Our investigation revealed that 52 (37.4%) out of 139 BBC patients harbored germline PVs in high- and intermediate-penetrance breast cancer (BC) susceptibility genes including BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, RAD51C. Nineteen out of 53 positively tested patients harbored a PV in a known BC susceptibility gene (no-BRCA). Interestingly, in the absence of an analysis performed via multi-gene panel, a significant proportion (14.4%) of PVs would have been lost. Therefore, offering a NGS-based multi-gene panel testing to all BBC patients may significantly increase the detection rates of germline PVs in other cancer susceptibility genes beyond BRCA1/2, avoiding underestimation of the number of individuals affected by a hereditary tumor syndrome. |
format | Online Article Text |
id | pubmed-7564956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75649562020-10-26 Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 Fanale, Daniele Incorvaia, Lorena Filorizzo, Clarissa Bono, Marco Fiorino, Alessia Calò, Valentina Brando, Chiara Corsini, Lidia Rita Barraco, Nadia Badalamenti, Giuseppe Russo, Antonio Bazan, Viviana Cancers (Basel) Article SIMPLE SUMMARY: Many bilateral breast cancer patients with increased hereditary susceptibility to breast cancer result negative for BRCA1 or BRCA2 pathogenic variants and, thus, need a further genetic testing through a broader gene panel. Some patients with negative test result for BRCA1/2 pathogenic variants may harbor pathogenic variants in other breast cancer susceptibility genes, including ATM, CHEK2, PALB2, PTEN, TP53. Of course, the use of a multi-gene panel provides clinicians more information through a single test. Therefore, we focused on potential clinical impact of a NGS-based multi-gene panel testing in bilateral breast cancer patients, in order to evaluate the utility of perform a most comprehensive genetic analysis in these subjects, regardless the criteria concerning personal and family history of cancer established by the current guidelines. Our study revealed that the use of a NGS-based multiple-gene panel testing could increase the detection rates of germline alterations in bilateral breast cancer patients. ABSTRACT: Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast cancer (BBC). The annual risk of contralateral BC is about 0.5%, but increases by up to 3% in BRCA1 or BRCA2 pathogenic variant (PV) carriers. Our study was aimed to evaluate whether all BBC patients should be offered multi-gene panel testing, regardless their cancer family history and age at diagnosis. We retrospectively collected all clinical information of 139 BBC patients genetically tested for germline PVs in different cancer susceptibility genes by NGS-based multi-gene panel testing. Our investigation revealed that 52 (37.4%) out of 139 BBC patients harbored germline PVs in high- and intermediate-penetrance breast cancer (BC) susceptibility genes including BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, RAD51C. Nineteen out of 53 positively tested patients harbored a PV in a known BC susceptibility gene (no-BRCA). Interestingly, in the absence of an analysis performed via multi-gene panel, a significant proportion (14.4%) of PVs would have been lost. Therefore, offering a NGS-based multi-gene panel testing to all BBC patients may significantly increase the detection rates of germline PVs in other cancer susceptibility genes beyond BRCA1/2, avoiding underestimation of the number of individuals affected by a hereditary tumor syndrome. MDPI 2020-08-25 /pmc/articles/PMC7564956/ /pubmed/32854451 http://dx.doi.org/10.3390/cancers12092415 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fanale, Daniele Incorvaia, Lorena Filorizzo, Clarissa Bono, Marco Fiorino, Alessia Calò, Valentina Brando, Chiara Corsini, Lidia Rita Barraco, Nadia Badalamenti, Giuseppe Russo, Antonio Bazan, Viviana Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
title | Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
title_full | Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
title_fullStr | Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
title_full_unstemmed | Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
title_short | Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 |
title_sort | detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by multi-gene panel testing: impact of pathogenic variants in other genes beyond brca1/2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564956/ https://www.ncbi.nlm.nih.gov/pubmed/32854451 http://dx.doi.org/10.3390/cancers12092415 |
work_keys_str_mv | AT fanaledaniele detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT incorvaialorena detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT filorizzoclarissa detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT bonomarco detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT fiorinoalessia detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT calovalentina detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT brandochiara detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT corsinilidiarita detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT barraconadia detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT badalamentigiuseppe detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT russoantonio detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 AT bazanviviana detectionofgermlinemutationsinacohortof139patientswithbilateralbreastcancerbymultigenepaneltestingimpactofpathogenicvariantsinothergenesbeyondbrca12 |